GO:0001882 nucleoside binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0001882 (nucleoside binding) is a molecular function defined as binding to a nucleoside, a compound consisting of a purine or pyrimidine nitrogenous base linked either to ribose or deoxyribose.
• Nucleoside binding underlies RNA metabolism, nucleotide analogue drug action, DNA methylation, and bacterial conjugative element acquisition [1,2,5].
• Nucleoside and non-nucleoside inhibitors of viral polymerases, such as SARS-CoV-2 RdRp and HCV NS5B, are validated through nucleoside binding studies [3,6,7].
• Plant nucleoside N-ribohydrolases use riboside binding to mobilize nitrogen stores, linking nucleoside binding to primary metabolism.
• Nucleoside-loaded nanomedicines exploit nucleoside binding and transport for targeted drug delivery.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal testing of nucleoside-binding proteins in disease and drug response.
Description
Nucleoside binding (GO:0001882) is a molecular function describing the selective interaction of a protein or nucleic acid with a nucleoside, a compound consisting of a purine or pyrimidine nitrogenous base linked either to ribose or deoxyribose. This function is central to RNA dynamics, nucleotide analogue pharmacology, and RNA-binding protein analysis, where nucleoside or nucleotide analogues are used as chemical probes to label and interrogate RNA-protein interactions. Because nucleosides are the building blocks of RNA and the precursors of DNA, proteins that bind them sit at the interface of transcription, translation, and metabolic regulation [1,5]. Researchers study nucleoside binding to understand how enzymes discriminate between ribose and deoxyribose substrates, how antiviral and anticancer analogues are recognized, and how pathogens acquire mobile genetic elements [2,3,4]. The term is also relevant to biotechnology, where nucleoside-loaded nanomedicines are engineered for controlled delivery. In this article, we integrate the QuickGO definition with verified PubMed literature to outline the mechanism, key genes, disease links, and experimental methods for studying nucleoside binding.
nucleoside binding At A Glance
| GO ID | GO:0001882 |
|---|---|
| GO term | nucleoside binding |
| Ontology | molecular_function |
| Synonym | none |
| Major function | Binding to a nucleoside, a purine or pyrimidine base linked to ribose or deoxyribose |
| Ligand class | Nucleosides, including ribonucleosides and deoxyribonucleosides |
| Representative proteins | Viral RNA-dependent RNA polymerases, DNA methyltransferases, nucleoside N-ribohydrolases, nucleoside transporters |
| Related GO terms | nucleotide binding, RNA binding, nucleoside transmembrane transporter activity |
| Research relevance | Antiviral and anticancer drug design, RNA dynamics, DNA methylation, bacterial conjugation, plant nitrogen metabolism |
What Is GO:0001882?
GO:0001882 nucleoside binding is defined by QuickGO as binding to a nucleoside, a compound consisting of a purine or pyrimidine nitrogenous base linked either to ribose or deoxyribose. In practice, this means a protein or macromolecule forms non-covalent interactions with a nucleoside ligand, often through hydrogen bonding, stacking, and shape complementarity. The term covers binding to both ribonucleosides and deoxyribonucleosides and is distinct from nucleotide binding, which involves a phosphate group. Nucleoside binding is a molecular function that can be assayed biochemically, structurally, and computationally, and it is frequently studied in the context of RNA-modifying enzymes, viral polymerases, and nucleoside transporters [1,3,5].
Why Is nucleoside binding Important in Cell Biology?
Nucleoside binding is important because it governs how cells and pathogens recognize the building blocks of RNA and DNA, and it is the molecular basis for a large class of therapeutic agents. Nucleoside and nucleotide analogues are widely used to probe RNA dynamics and RNA-binding proteins, and their binding specificity determines drug efficacy and toxicity. In viral infections, nucleoside inhibitors of SARS-CoV-2 RdRp and non-nucleoside inhibitors of HCV NS5B rely on distinct binding modes that can be characterized by docking and molecular dynamics [3,6,7]. In bacteria, nucleoside binding by a surface lipoprotein controls conjugative ICE acquisition, linking this function to horizontal gene transfer and antibiotic resistance. In plants, riboside binding by N-ribohydrolases regulates nitrogen storage mobilization. DNA methyltransferases use nucleoside-driven specificity to recognize their substrates, connecting nucleoside binding to epigenetic regulation. Finally, nucleoside-loaded nanomedicines exploit these interactions for targeted delivery.
• Provides the molecular basis for nucleoside and nucleotide analogue drugs used against viral polymerases [3,6,7].
• Enables chemical probing of RNA dynamics and RNA-binding proteins.
• Controls bacterial conjugative ICE acquisition and horizontal gene transfer.
• Regulates plant nitrogen storage mobilization through riboside binding.
• Underpins DNA methyltransferase substrate specificity and epigenetic marking.
• Supports nanomedicine design through nucleoside-loaded delivery systems.
• Links to antiviral drug discovery for SARS-CoV-2 and HCV [3,6,7].
• Connects to cancer and antiviral therapy through nucleoside analogue metabolism [1,8].
• Provides a target for structural and computational drug screening [3,6,7].
• Enables CRISPR-based causal testing of nucleoside-binding proteins in disease models.
Molecular Mechanism of nucleoside binding
Ligand recognition and binding pocket architecture
In simple terms: The protein has a pocket that fits a nucleoside like a lock fits a key.
Nucleoside binding typically occurs in a pocket that recognizes the purine or pyrimidine base and the ribose or deoxyribose sugar. Structural and computational studies of SARS-CoV-2 RdRp show that nucleoside analogues occupy the active site with specific hydrogen bonds and stacking interactions [3,7]. Non-nucleoside inhibitors of HCV NS5B bind allosteric sites, demonstrating that nucleoside binding can be modulated at sites distinct from the catalytic center. These studies highlight the importance of shape complementarity and electrostatic interactions in nucleoside recognition [3,6,7].
Ribose versus deoxyribose discrimination
In simple terms: The protein can tell the difference between RNA sugar and DNA sugar.
Nucleoside binding proteins often discriminate between ribose and deoxyribose, which is critical for selecting RNA versus DNA substrates. DNA methyltransferases use nucleoside-driven specificity to recognize their target bases, ensuring correct methylation patterns. Plant nucleoside N-ribohydrolases bind ribosides and cleave them to release nitrogen for storage mobilization, illustrating sugar-specific recognition. This discrimination is achieved through hydrogen bonding networks and steric constraints in the binding pocket [4,5].
Conformational dynamics and induced fit
In simple terms: The protein changes shape when the nucleoside binds.
Nucleoside binding is often accompanied by conformational changes that stabilize the ligand and prepare the protein for catalysis or transport. Molecular dynamics simulations of SARS-CoV-2 RdRp with nucleoside and non-nucleoside inhibitors reveal dynamic binding modes and affinity differences. Biostructural models for nucleoside analog binding to SARS-CoV-2 RdRp provide insight into how conformational flexibility affects inhibitor residence time. These dynamic features are essential for understanding drug potency and resistance [3,7].
Allosteric and surface binding modes
In simple terms: Some proteins bind nucleosides on their surface or at sites far from the active center.
Nucleoside binding is not limited to catalytic pockets. A surface lipoprotein in mycoplasmas binds nucleosides to govern conjugative ICE acquisition, showing that surface-exposed binding sites can control horizontal gene transfer. Non-nucleoside inhibitors of HCV NS5B bind allosteric sites, demonstrating that nucleoside binding can be regulated at remote locations. These examples expand the functional repertoire of nucleoside binding beyond classical enzyme active sites [2,6].
Chemical probing and analogue recognition
In simple terms: Synthetic nucleoside analogues are used to tag and study RNA.
Nucleoside and nucleotide analogues are applied in RNA dynamics and RNA-binding protein analysis, where they are incorporated into RNA or used as affinity probes. Nucleoside-loaded nanomedicines further exploit analogue recognition for delivery. These applications depend on the ability of proteins to bind nucleoside analogues with sufficient specificity, making binding studies central to probe design [1,8].
Key Genes Involved in GO:0001882 nucleoside binding
The following genes and proteins represent major nucleoside-binding functions across viral, bacterial, plant, and human systems, as supported by the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| RdRp (SARS-CoV-2) | Binds nucleoside inhibitors at the active site | Antiviral drug design and molecular dynamics [3,7] |
| NS5B (HCV) | Binds non-nucleoside inhibitors at allosteric sites | Allosteric inhibitor development |
| DNA methyltransferase | Uses nucleoside-driven specificity for base recognition | Epigenetic regulation and inhibitor design |
| Nucleoside N-ribohydrolase | Binds ribosides for nitrogen mobilization | Plant nitrogen storage and metabolism |
| Surface lipoprotein (mycoplasma) | Binds nucleosides to govern ICE acquisition | Horizontal gene transfer and resistance |
| Nucleoside transporters | Bind nucleosides for cellular uptake | Nucleoside analogue pharmacology [1,8] |
| RNA-binding proteins | Bind nucleoside analogues in RNA probes | RNA dynamics and interactome analysis |
| Nucleoside kinases | Bind nucleosides as substrates for phosphorylation | Prodrug activation and antiviral therapy |
| Nucleoside diphosphate kinases | Bind nucleosides in phosphate transfer | Nucleotide metabolism |
| SAM-dependent methyltransferases | Bind nucleoside moieties in cofactor interactions | Methylation and epigenetics |
| Viral polymerases (other) | Bind nucleoside analogues for chain termination | Broad-spectrum antiviral design [3,6] |
| Nucleoside hydrolases | Bind nucleosides for hydrolysis | Parasite metabolism and drug targets |
| Nucleoside phosphorylases | Bind nucleosides in reversible phosphorolysis | Nucleoside salvage pathways |
| Nucleoside deaminases | Bind nucleosides for deamination | RNA editing and drug metabolism |
| Nucleoside transporters (CNT/ENT) | Bind nucleosides for membrane transport | Nucleoside drug delivery |
| Nucleoside-binding lectins | Bind nucleosides in recognition processes | Host-pathogen interactions |
| Nucleoside-responsive riboswitches | Bind nucleosides to regulate gene expression | RNA-based regulation |
How Is nucleoside binding Regulated?
Nucleoside binding can be regulated at multiple levels. Allosteric sites on viral polymerases allow non-nucleoside inhibitors to modulate binding without competing with the active site. Conformational dynamics and induced fit regulate the affinity and residence time of nucleoside analogues, as shown for SARS-CoV-2 RdRp [3,7]. In bacteria, surface lipoprotein-mediated nucleoside binding controls conjugative ICE acquisition, suggesting that environmental nucleoside levels regulate horizontal gene transfer. In plants, riboside binding by N-ribohydrolases is tied to nitrogen storage mobilization, linking nutrient status to enzyme activity. DNA methyltransferases use nucleoside-driven specificity to regulate methylation patterns, which can be influenced by cellular nucleoside pools. These examples indicate that nucleoside binding is not a static property but a regulated interaction influenced by ligand availability, allostery, and cellular metabolism [2,3,4,5,6,7].
nucleoside binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| RdRp (SARS-CoV-2) | COVID-19 and antiviral resistance | Point-mutation knock-in of resistance mutations in viral replicon |
| NS5B (HCV) | Hepatitis C and allosteric inhibitor response | Knockout of NS5B in HCV replicon system |
| DNA methyltransferase | Cancer epigenetics and methylation disorders | Knockout and point-mutation in cancer cell lines |
| Nucleoside N-ribohydrolase | Plant nitrogen storage and metabolism | Knockout in Arabidopsis or crop species |
| Surface lipoprotein (mycoplasma) | Bacterial conjugation and resistance spread | Knockout and overexpression in mycoplasma models |
Viral infections and antiviral resistance
Nucleoside binding is central to the mechanism of antiviral drugs targeting SARS-CoV-2 RdRp and HCV NS5B. Molecular screening, docking, and dynamics studies have characterized how nucleoside and non-nucleoside inhibitors bind these polymerases, informing drug design and resistance monitoring [3,6,7]. Mutations in the binding pocket can alter drug affinity, making nucleoside binding studies essential for surveillance [3,7].
Cancer and epigenetic therapy
DNA methyltransferases use nucleoside-driven specificity to recognize substrates, and their inhibition is a strategy in epigenetic cancer therapy. Nucleoside analogues are also used as anticancer agents, where binding and incorporation into DNA or RNA affect cell proliferation. Understanding nucleoside binding helps predict off-target effects and resistance [1,5].
Bacterial conjugation and antibiotic resistance
Nucleoside binding by a surface lipoprotein governs conjugative ICE acquisition in mycoplasmas, linking this molecular function to horizontal gene transfer and the spread of resistance determinants. This finding suggests that nucleoside availability in the environment can influence the acquisition of mobile genetic elements.
Plant nitrogen metabolism and storage
Plant nucleoside N-ribohydrolases bind ribosides to mobilize nitrogen stores, connecting nucleoside binding to primary metabolism and stress responses. This has implications for crop nitrogen use efficiency and storage mobilization.
From nucleoside binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does a candidate gene causally bind nucleosides? | CRISPR knockout followed by biochemical binding assay |
| Does a specific residue mediate nucleoside binding? | Point-mutation knock-in of the binding residue |
| Can a disease-associated mutation alter binding affinity? | Knock-in of the patient mutation in a cell line |
| Where does the protein localize during nucleoside binding? | Tagged knock-in with fluorescent or affinity tag |
| Does overexpression change drug sensitivity? | Overexpression cell model with nucleoside analogue treatment |
| Which genes regulate nucleoside binding networks? | CRISPR library screening with nucleoside analogue selection |
How to Study the nucleoside binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Isothermal titration calorimetry | Binding affinity and stoichiometry | Nucleoside-protein interaction validation |
| Molecular docking | Predicted binding pose and score | Virtual screening of nucleoside inhibitors [3,6] |
| Molecular dynamics simulation | Binding stability and conformational changes | SARS-CoV-2 RdRp inhibitor studies [3,7] |
| Chemical probing with analogues | RNA dynamics and protein-RNA interactions | RNA-binding protein analysis |
| CRISPR knockout | Gene requirement for nucleoside binding | Causal gene discovery [2,5] |
| CRISPR library screening | Genome-wide modifiers of nucleoside response | Drug resistance and sensitivity screens |
| Overexpression | Gain-of-function effects on binding | Drug sensitivity testing |
| Structural biology (cryo-EM/X-ray) | Atomic details of binding pocket | Rational drug design |
Biochemical binding assays
Nucleoside binding can be measured using equilibrium dialysis, isothermal titration calorimetry, and fluorescence polarization with labeled nucleosides. These assays provide dissociation constants and stoichiometry, and are essential for validating hits from screening [1,3].
Structural and computational approaches
Molecular docking and molecular dynamics simulations are widely used to model nucleoside and non-nucleoside inhibitor binding to viral polymerases, as demonstrated for SARS-CoV-2 RdRp and HCV NS5B [3,6,7]. Biostructural models help predict binding modes and guide medicinal chemistry.
Chemical probing and RNA dynamics
Nucleoside and nucleotide analogues are applied in RNA dynamics and RNA-binding protein analysis, enabling metabolic labeling and interactome capture. These methods link nucleoside binding to RNA fate and protein-RNA networks.
Genetic and CRISPR screens
CRISPR knockout and library screening can identify genes required for nucleoside binding, uptake, and drug response. Overexpression and point-mutation models further test causality and mechanism [2,5].
How CRISPR Can Be Used to Study GO:0001882 nucleoside binding
Knockout
CRISPR knockout of candidate nucleoside-binding genes can abolish binding and reveal downstream phenotypes. For example, knocking out a surface lipoprotein in mycoplasma would test its role in conjugative ICE acquisition. Knockout of DNA methyltransferases can confirm nucleoside-driven specificity in methylation.
Point Mutation
Point mutations in the binding pocket can dissect the contribution of individual residues to nucleoside binding. This is particularly useful for viral polymerases, where resistance mutations alter inhibitor binding [3,7]. Point-mutation knock-in models can validate structural predictions.
Knock-in
Knock-in of disease-associated or resistance mutations allows testing of their effect on nucleoside binding affinity and drug response. This approach is valuable for SARS-CoV-2 RdRp and HCV NS5B variants [3,6,7]. Tagged knock-in can also enable localization and interaction studies.
Overexpression
Overexpression of nucleoside-binding proteins can sensitize cells to nucleoside analogues or alter flux through metabolic pathways. This is useful for studying nucleoside transporters and kinases in drug uptake and activation [1,8]. Overexpression models also help identify dominant-negative or gain-of-function effects.
How EDITGENE Supports nucleoside binding Research
Researchers studying nucleoside binding-related genes often need to determine whether a candidate gene is causally involved in ligand recognition, drug response, or disease phenotypes. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell models that answer these questions.
Contact EDITGENE today to design your custom CRISPR model for nucleoside binding research.
Frequently Asked Questions About nucleoside binding
What is nucleoside binding?
Nucleoside binding (GO:0001882) is a molecular function defined as binding to a nucleoside, a compound consisting of a purine or pyrimidine nitrogenous base linked either to ribose or deoxyribose.
What genes are involved in nucleoside binding?
Genes include viral RdRp and NS5B, DNA methyltransferases, nucleoside N-ribohydrolases, nucleoside transporters, and bacterial surface lipoproteins [2,3,4,5,6,7].
What is the GO ID for nucleoside binding?
The GO ID for nucleoside binding is GO:0001882.
How is nucleoside binding studied?
It is studied using biochemical binding assays, molecular docking, molecular dynamics, chemical probing with analogues, and CRISPR screens [1,3,6,7].
Why is nucleoside binding important for antiviral drugs?
Nucleoside and non-nucleoside inhibitors of viral polymerases rely on nucleoside binding for their mechanism, as shown for SARS-CoV-2 RdRp and HCV NS5B [3,6,7].
Does nucleoside binding occur in bacteria?
Yes, a surface lipoprotein in mycoplasmas binds nucleosides to govern conjugative ICE acquisition.
What is the difference between nucleoside binding and nucleotide binding?
Nucleoside binding involves a base linked to a sugar, while nucleotide binding involves a base linked to a sugar and one or more phosphate groups.
Can CRISPR be used to study nucleoside binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models can test the causal role of nucleoside-binding proteins [2,5].
What diseases are linked to nucleoside binding?
Viral infections, cancer epigenetics, bacterial resistance spread, and plant nitrogen metabolism are linked to nucleoside binding [2,3,4,5,6,7].
What are nucleoside-loaded nanomedicines?
Nucleoside-loaded nanomedicines are delivery systems that exploit nucleoside binding and transport for targeted therapy.
Conclusion
Nucleoside binding (GO:0001882) is a fundamental molecular function that connects RNA and DNA metabolism, antiviral drug action, epigenetic regulation, bacterial conjugation, and plant nitrogen storage. The verified literature demonstrates its broad relevance across viral polymerases, DNA methyltransferases, nucleoside hydrolases, and surface lipoproteins [1,2,3,4,5,6,7,8]. Understanding the structural and dynamic basis of nucleoside binding is essential for drug design and for interpreting disease-associated mutations. CRISPR-based models provide a powerful way to test causality and mechanism, and EDITGENE offers the tools to build these models efficiently.
References
- 1. Zheng M et al.. 2022. Application of nucleoside or nucleotide analogues in RNA dynamics and RNA-binding protein analysis.. Wiley Interdiscip Rev RNA 13(6):e1722 PMID: 35218164
- 2. Derriche M et al.. 2026. Nucleoside binding by a surface lipoprotein governs conjugative ICE acquisition in mycoplasmas.. mBio 17(2):e0293925 PMID: 41467788
- 3. Chinnamadhu A et al.. 2023. Dynamics and binding affinity of nucleoside and non-nucleoside inhibitors with RdRp of SARS-CoV-2: a molecular screening, docking, and molecular dynamics simulation study.. J Biomol Struct Dyn 41(20):10396-10410 PMID: 36510678
- 4. Ľuptáková E et al.. 2024. Plant nucleoside N-ribohydrolases: riboside binding and role in nitrogen storage mobilization.. Plant J 117(5):1432-1452 PMID: 38044809
- 5. Gade M et al.. 2023. Nucleoside-Driven Specificity of DNA Methyltransferase.. Chembiochem 24(22):e202300094 PMID: 37548117
- 6. Cao H et al.. 2008. Non-nucleoside inhibitors of NS5B polymerase binding to allosteric sites: 3D- QSAR and molecular docking studies.. Curr Med Chem 15(15):1462-77 PMID: 18537623
- 7. Prussia AJ et al.. 2021. Biostructural Models for the Binding of Nucleoside Analogs to SARS-CoV-2 RNA-Dependent RNA Polymerase.. J Chem Inf Model 61(3):1402-1411 PMID: 33655751
- 8. Zhou Z et al.. 2023. Research progress on the nucleoside/nucleotide-loaded nanomedicines.. Zhejiang Da Xue Xue Bao Yi Xue Ban 52(3):279-284 PMID: 37476939
